Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/3/2017
SIETES contiene 91704 citas

 
 
 1 a 20 de 2073 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Sondergaard KB, Weeke P, Wissenberg M, Olsen A-MS, Fosbol EL, Lippert FK, Torp-Pedersen C, Gislason GH, Folke F. Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case–time–control study. Eur Heart J 2017;3:100-7. [Ref.ID 101478]
2. Cita con resumen
Anónimo. Mirabégron: fibrillations auriculaires. Prescrire 2017;37:25. [Ref.ID 101365]
3.
Felson DT. Safety of nonsteroidal antiinflammatory drugs.. N Engl J Med 2016;373:2595-6. [Ref.ID 101348]
4. Cita con resumen
Anónimo. Celecoxib safety revisited. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:159. [Ref.ID 101041]
5.Enlace a cita original Cita con resumen
Anónimo. Anticonceptivos hormonales: selección adecuada. Boletín Terapéutico Andaluz 2016;31:1-10. [Ref.ID 101040]
6. Cita con resumen
Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckeman B, Berger MF, Bao W, Lincoff AM, for the PRECISION Trial Investigators. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016;373:2519-29. [Ref.ID 101038]
7.Enlace a cita original Cita con resumen
Martinez C, Suissa S, McGill J, Rietbrock S, Katholing A, Freedman B, Cohen AT, Handelsman DJ. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ 2016;355:i5968. [Ref.ID 101016]
9.Enlace a cita original Cita con resumen
Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol 2016;82:957-64. [Ref.ID 100827]
10.Tiene citas relacionadas Cita con resumen
Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G, on behalf of the Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857. [Ref.ID 100756]
11.Tiene citas relacionadas Cita con resumen
Gislason GH, Torp-Pedersen C. NSAIDs and the failing heart. BMJ 2016;354:i5163. [Ref.ID 100755]
12. Cita con resumen
Hemkens LG, Ewald H, Briel M. Colchicine and prevention of cardiovascular events. JAMA 2016;316:1106-007. [Ref.ID 100745]
13. Cita con resumen
McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z, Chen G, Du B, McArdle N, Mukherjee S, Tripathi M, Billot L, Li Q, Lorenzi-Filho G, Barbe F, Redline S, Wang J, Arima H, Neal B, White DP, Grunstein RR, Zhong N, Anderson CS, SAVE Investigators and Coordinators. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 2016;375:919-31. [Ref.ID 100743]
14.Enlace a cita original
Yu Z-h, Jiang H-y, Zhou YY, Shi H-y, Ruan B. Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis. Br J Clin Pharmacol 2016;82:624-32. [Ref.ID 100731]
15.Enlace a cita original
Root AA, Wong AYS, Ghebremichael-Weldeselassie Y, Smeeth L, Bhaskaran K, Evans SJW, Brauer R, Wong ICK, Navaratnam V, Douglas I. Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs. Br J Clin Pharmacol 2016;82:512-21. [Ref.ID 100691]
16.Enlace a cita original
Renoux C, Dell'Aniello S, Khairy P, Marras C, Bugden S, Turin TC, Blais L, Tamim H, Evans C, Steele R, Dormuth C, Ernst P, the Canadian Network for Observational Drug Effect Studies (CNODES) investigators. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. Br J Clin Pharmacol 2016;82:461-72. [Ref.ID 100688]
17. Cita con resumen
Casassus B. Drug scandals in France: have the lessons been learnt?. Lancet 2016;388:550-2. [Ref.ID 100574]
18. Cita con resumen
Anónimo. Citalopram, escitalopram et allongements de l'intervalle QT. Prescrire 2016;36:348-51. [Ref.ID 100539]
19.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
20. Cita con resumen
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, for the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:28 de julio. [Ref.ID 100511]
Seleccionar todas
 
 1 a 20 de 2073 siguiente >>